Free Trial

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

IDEXX Laboratories logo
$501.57 -3.26 (-0.65%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$501.54 -0.03 (-0.01%)
As of 05/23/2025 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Key Stats

Today's Range
$496.61
$502.18
50-Day Range
$361.04
$521.68
52-Week Range
$356.14
$530.60
Volume
443,606 shs
Average Volume
649,917 shs
Market Capitalization
$40.34 billion
P/E Ratio
47.01
Dividend Yield
N/A
Price Target
$536.00
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

IDXX MarketRank™: 

IDEXX Laboratories scored higher than 71% of companies evaluated by MarketBeat, and ranked 314th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEXX Laboratories has only been the subject of 2 research reports in the past 90 days.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 13.83% in the coming year, from $11.93 to $13.58 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 47.01, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.47.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 47.01, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.83.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 3.41. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 25.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IDEXX Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    3.61% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 4.33%, indicating that investor sentiment is improving.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.61% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 4.33%, indicating that investor sentiment is improving.
  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 38 news articles for IDEXX Laboratories this week, compared to 16 articles on an average week.
  • Search Interest

    8 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,182,920.00 in company stock.

  • Percentage Held by Insiders

    Only 0.98% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $413.44 on January 1st, 2025. Since then, IDXX stock has increased by 21.3% and is now trading at $501.57.
View the best growth stocks for 2025 here
.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings results on Thursday, May, 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. The business's revenue for the quarter was up 3.6% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional shareholders of IDEXX Laboratories include Vanguard Group Inc. (12.16%), Price T Rowe Associates Inc. MD (2.47%), Invesco Ltd. (1.45%) and Principal Financial Group Inc. (1.39%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, James F Polewaczyk, George Fennell, Kathy V Turner, Michael Lane, Daniel M Junius, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin.
View institutional ownership trends
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

Last Earnings
5/01/2025
Today
5/24/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
Employees
10,800
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$536.00
High Stock Price Target
$580.00
Low Stock Price Target
$500.00
Potential Upside/Downside
+6.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
47.01
Forward P/E Ratio
42.04
P/E Growth
3.41
Net Income
$887.87 million
Pretax Margin
28.48%

Debt

Sales & Book Value

Annual Sales
$3.93 billion
Cash Flow
$12.56 per share
Price / Cash Flow
39.92
Book Value
$19.48 per share
Price / Book
25.75

Miscellaneous

Free Float
80,157,000
Market Cap
$40.34 billion
Optionable
Optionable
Beta
1.52

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:IDXX) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners